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brain barrier from degradation in an Alzheimer’s 
disease mouse model
Yujie Ding1, Yu Zhong1, Andrea Baldeshwiler2, Erin L. Abner1,5, Björn Bauer3 and Anika M. S. Hartz1,4,6* 
Abstract 
Background: Failure to clear Aβ from the brain is partly responsible for Aβ brain accumulation in Alzheimer’s disease 
(AD). A critical protein for clearing Aβ across the blood-brain barrier is the efflux transporter P-glycoprotein (P-gp). In 
AD, P-gp levels are reduced, which contributes to impaired Aβ brain clearance. However, the mechanism responsible 
for decreased P-gp levels is poorly understood and there are no strategies available to protect P-gp. We previously 
demonstrated in isolated brain capillaries ex vivo that human Aβ40 (hAβ40) triggers P-gp degradation by activating 
the ubiquitin-proteasome pathway. In this pathway, hAβ40 initiates P-gp ubiquitination, leading to internalization 
and proteasomal degradation of P-gp, which then results in decreased P-gp protein expression and transport activity 
levels. Here, we extend this line of research and present results from an in vivo study using a transgenic mouse model 
of AD (human amyloid precursor protein (hAPP)-overexpressing mice; Tg2576).
Methods: In our study, hAPP mice were treated with vehicle, nocodazole (NCZ, microtubule inhibitor to block P-gp 
internalization), or a combination of NCZ and the P-gp inhibitor cyclosporin A (CSA). We determined P-gp protein 
expression and transport activity levels in isolated mouse brain capillaries and Aβ levels in plasma and brain tissue.
Results: Treating hAPP mice with 5 mg/kg NCZ for 14 days increased P-gp levels to levels found in WT mice. Consist-
ent with this, P-gp-mediated hAβ42 transport in brain capillaries was increased in NCZ-treated hAPP mice compared 
to untreated hAPP mice. Importantly, NCZ treatment significantly lowered hAβ40 and hAβ42 brain levels in hAPP 
mice, whereas hAβ40 and hAβ42 levels in plasma remained unchanged.
Conclusions: These findings provide in vivo evidence that microtubule inhibition maintains P-gp protein expression 
and transport activity levels, which in turn helps to lower hAβ brain levels in hAPP mice. Thus, protecting P-gp at the 
blood-brain barrier may provide a novel therapeutic strategy for AD and other Aβ-based pathologies.
Keywords: Blood–brain barrier, P-glycoprotein, Alzheimer’s disease, Brain capillaries, Amyloid beta, Ubiquitin-
proteasome system
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Introduction
One hallmark of Alzheimer’s disease (AD) is the accu-
mulation of neurotoxic amyloid beta (Aβ) in the brain 
[1]. This accumulation of soluble and insoluble Aβ 
forms contributes to neurodegeneration and demen-
tia observed in AD [2]. Increasing evidence from recent 
studies indicates that Aβ brain accumulation is, in part, 
due to impaired Aβ clearance from the brain across the 
blood-brain barrier into the blood [3–5]. Results from 
multiple studies show that the ATP-driven efflux trans-
porter P-glycoprotein (P-gp) transports Aβ, and thus, 
is involved in clearing Aβ from the brain [6–14]. In this 
regard, Callaghan et  al. used different software docking 
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programs to predict P-gp interactions with Aβ. The 
obtained models suggest that Aβ40 vertically enters the 
central cavity of P-gp [7]. Several studies using tissue 
samples from AD patients have shown that blood-brain 
barrier P-gp protein expression levels are decreased com-
pared to cognitive normal individuals [15–18]. Recent 
data show a 53% reduction (p < 0.01) in P-gp protein 
levels in capillaries from AD patient brain samples com-
pared to samples from control individuals [19]. Consist-
ent with decreased P-gp expression levels, results of PET 
studies indicate compromised P-gp activity levels in AD 
patients [20, 21]. Thus, existing studies support the con-
clusion that blood-brain barrier P-gp protein expression 
and transport activity are decreased in AD. Results from 
our own studies using a transgenic mouse AD model 
(human amyloid precursor protein (hAPP)-overexpress-
ing mice; Tg2576) support these observations and sug-
gest a link between high hAβ levels and decreased brain 
capillary P-gp expression and activity levels in AD [9, 22, 
23]. Moreover, we found that hAβ40 causes P-gp degra-
dation in brain capillaries [22, 23]. Specifically, we dem-
onstrated that hAβ40 triggers P-gp degradation through 
activation of the ubiquitin-proteasome pathway: first, 
P-gp is ubiquitinated; second, P-gp is internalized; and 
finally, P-gp is degraded by the proteasome [22, 24]. In 
a recent study we showed that preventing P-gp ubiquit-
ination by inhibiting the ubiquitin-activating enzyme E1 
protects blood-brain barrier P-gp expression and activ-
ity levels and lowers hAβ brain levels in young hAPP 
mice [23]. Here, we extend our work and show that dos-
ing 8-week old hAPP mice with the potent microtubule 
depolymerization inhibitor nocodazole (NCZ) protects 
P-gp protein expression and transport activity and lowers 
hAβ brain levels.
Thus, protecting P-gp from internalization and degra-
dation at the blood-brain barrier could be one strategy to 
improve Aβ clearance from the brain.
Materials and methods
Experimental design and statistical analysis
Sample sizes (i.e., animal numbers, brain capillary sam-
ple size, number of liver tissue samples) were based on 
power analyses of preliminary data and past published 
work [9, 22, 23, 25]. Sample size and the number of rep-
etitions are reported in the Results section and the cor-
responding figure legends.
Results are presented as mean ± SEM, or percent 
change, as indicated. One-way analysis of variance, with 
factor treatment group, was used to assess mean differ-
ences in outcomes. Tukey’s HSD post-hoc test was used 
to preserve the family-wise Type 1 error rate at 5%. 
Post hoc tests were not performed when the omnibus 
F statistic was not significant. Statistical analyses were 
completed using SAS 9.4® (SAS Institute, Inc.; Cary, NC, 
USA).
Animals
  The Institutional Animal Care and Use Committee at 
the University of Minnesota (Protocol #1110A05865, 
principal investigator; PI: Hartz, AMS) approved all 
animal experiments, which were conducted in accord-
ance with AAALAC regulations, the Guide of the Care 
and Use of Laboratory Animals of the NIH, and the US 
Department of Agriculture Animal Welfare Act.
 Male wild type mice (WT; RRID: IMSR_TAC:2789; 
n = 10) and male transgenic hAPP-overexpressing 
mice (Tg2576 strain; 129S6.CgTg(APPSWE2576Kha; 
RRID:IMSR_TAC:2789; n = 45) were acquired from 
Taconic Farms (Germantown, NY, USA). Mice were 
received at age 8–12 weeks and were housed individu-
ally in an AAALAC-accredited temperature-and-humid-
ity-controlled vivarium (23 °C, 35% relative humidity, 
12  h light-dark cycle) and allowed to habituate to their 
environment for two weeks prior to experiments. Mice 
had ad libidum access to tap water and standard rodent 
feed (Harlan Teklad Chow 2918, Harlan Laboratories 
Inc., Indianapolis, NJ, USA). Mice used for experiments 
were 10–14 weeks old and had a mean body weight of 
27.4 ± 1.1 g (mean ± SD) and 27.6 ± 2.7 g (mean ± SD) for 
WT and hAPP strains, respectively.
Chemicals
Antibodies against β-actin (ab8226; RRID: AB_306371), 
human Aβ40 (ab12265; RRID:AB_298985), human Aβ42 
(ab12267; RRID:AB_298987), as well as cyclosporin A 
(CSA; ab120114) were purchased from Abcam (Cam-
bridge, MA, USA). Modified Dulbecco’s phosphate 
buffered saline (DPBS) with 0.9 mM  Ca2+ and 0.5 mM 
 Mg2+ was purchased from HyClone (Logan, UT, USA). 
Complete™ protease inhibitor was purchased from 
Roche (Mannheim, Germany). C219 antibody against 
P-gp was purchased from ThermoFisher (MA126528; 
RRID:AB_795165; Waltham, MA, USA). Fluorescein-
hAβ42 [fluorescein-Aβ(1− 42)] was purchased from 
rPeptide (Bogart, GA, USA). [N-(4-nitrobenzofurazan-
7-yl)-D-Lys8]-cyclosporin A (NBD-CSA) was custom-
synthesized by R. Wenger (Basel, Switzerland; [26]). 
PSC833 was a kind gift from Novartis (Basel, Switzer-
land). Nocodazole, the ALT Assay Kit (MAK052), Cel-
Lytic™ M,  Ficoll® PM 400, bovine serum albumin and 
all other chemicals were purchased at the highest grade 
from Sigma-Aldrich (St. Louis, MO, USA).
NCZ dosing
Mice were randomly divided into four treatment groups 
(Group 1: WT mice treated with vehicle, n = 10; Group 
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2: hAPP mice treated with vehicle, n = 15; Group 3: hAPP 
mice treated with nocodazole (NCZ), n = 15; and Group 
4: hAPP mice treated with cyclosporin A (CSA) and 
NCZ, n = 15). Mice were treated for a total of 14 days; the 
dosing regimens for NCZ and CSA are shown in Table 1. 
The dosing regimen and length of the treatment are 
based on our previously published study and preliminary 
experiments using NCZ [23]. Briefly, mice in Groups 1 
and 2 were treated daily with vehicle (i.p.) every three 
days for the entire duration of the experiment. Mice in 
Groups 3 and 4 were treated with 5 mg/kg of NCZ (i.p.) 
every 3 days (days 1, 4, 7, 10, and 13). On days when no 
NCZ was given, mice in Group 3 were treated with vehi-
cle (p.o.) and mice in Group 4 were treated with 25 mg/
kg CSA (p.o.).
Blood and tissue collection
At the end of the 14-day treatment period, all mice were 
euthanized by  CO2 inhalation and decapitated; brain tis-
sue, trunk blood, and liver were collected from each ani-
mal. Blood was stored in heparinized tubes and plasma 
was extracted from blood by centrifugation at 5000g for 
5 min at 4 °C. Brain and liver tissue were frozen in liquid 
nitrogen at the time of collection and stored at – 80 °C 
until further analysis.
ALT assay
Alanine aminotransferase activity (ALT) in liver tissue 
lysate was measured using an ALT activity kit (MAK052; 
Sigma-Millipore, St. Louis, MO, USA) according to the 
manufacturer’s instructions. Briefly, from each mouse 
40 mg of collected liver tissue were homogenized in 300 
µl of ALT Assay Buffer using a Power Gen 125 tissue 
homogenizer (Thermo Fisher Scientific, Hampton, NH, 
USA). Homogenized liver samples were centrifuged at 
15,000g for 15 min at 4 °C. Supernatant containing ALT 
from each liver sample was diluted 1:100 for ALT activ-
ity determination. 20 µl of the diluted samples was pipet-
ted in duplicates onto a 96-well microplate. Wells were 
treated with ALT Master Mix solution. Changes in color-
imetric intensity was measured at 570 nm over 30 min (5 
min reading intervals, 37 °C) using a Synergy™ H1 Hybrid 
Multi-Mode Reader (BioTek, Winooski, VT, USA).
The amount of generated pyruvate, a measure of ALT 
activity, was determined using a standard curve. ALT 
activity was calculated using Eq. (1).
ALT activity is reported as nmole/min/ml = milliunit/
mL (mU/ml), where one milliunit (mU) of ALT is defined 
as the amount of enzyme that generates 1.0 nmole of 
pyruvate per minute at 37 °C.
Tissue harvest and brain capillary isolation
Brain capillaries were isolated as previously described 
[22, 23, 27]. Following euthanasia with  CO2, brains were 
collected, dissected, and cleaned of meninges. Frontal 
cortex tissue (~ 10 mg/brain) was collected, snap frozen 
in liquid nitrogen, and stored at − 80 °C for Aβ analysis. 
The remaining brain tissue was homogenized in  Ca2+/
Mg2+-containing DPBS supplemented with 5 mM D-glu-
cose and 1 mM sodium pyruvate. The brain homogen-
ate was mixed with a 15%  Ficoll→ PM 400 solution and 
centrifuged at 5,800  g for 20 min at 4°C to yield capil-
lary-containing pellets. The pellets were separated and 
resuspended in 1% BSA-DPBS solution and the capillary 
suspension was filtered through a 300 µm nylon mesh 
and then passed through a glass bead column (glass bead 
diameter: 0.45–0.5 mm) with 1% BSA-DPBS. Capillaries 
were washed off the glass beads with 1% BSA-DPBS. The 
resulting capillary suspension was centrifuged at 1,500 g 
for 3 min at 4ºC and the pellet was washed three times 
with DPBS. Isolated capillaries were used for transport 
experiments, isolation of capillary crude membranes, or 
stored for later analysis at − 80 ºC.
Capillary Crude membrane isolation
Capillary crude membranes were obtained from freshly 
isolated brain capillaries as described in previous stud-
ies [27]. Isolated brain capillaries were homogenized in a 
cell lysis buffer (CellLytic™ M, Sigma-Aldrich, St. Louis, 
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(Sigma-Aldrich, St. Louis, MO, USA). The capillary 
homogenate was centrifuged at 10,000g for 15 min at 4 
°C to separate organelles and cellular debris. The super-
natant was then centrifuged at 100,000g for 90 min at 4°C 
to obtain a pellet containing brain capillary crude mem-
branes. Crude membranes were resuspended in buffer 
and stored at − 80 °C.
 Western blotting
Protein expression levels were determined by Western 
blot analysis as described in previous studies [9, 22]. Pro-
tein concentrations of brain capillary crude membrane 
samples and brain lysate samples were determined with 
the Bradford assay. The Invitrogen  NuPage® Bis-Tris 
electrophoresis and blotting system was used to per-
form all Western blots. Following protein transfer, blot-
ting membranes were blocked and incubated overnight 
with the primary antibody (P-gp: C219, 1 µg/ml; hAβ40: 
1 µg/ml; hAβ42: 1 µg/ml; β-Actin: 1 µg/ml). Blotting 
membranes were washed and incubated for 1 hour with 
horseradish peroxidase-conjugated ImmunoPure sec-
ondary IgG antibody (1:5000, 0.15 µg/ml; Thermo Fisher 
Scientific, Waltham, MA, USA). Proteins were detected 
using SuperSignal West Pico Chemiluminescent Sub-
strate (Thermo Fisher Scientific, Waltham, MA, USA). 
Protein bands were visualized using a Bio-Rad Chemi-
Doc XRS + gel documentation system. Optical density 
and digital molecular weight analyses were performed 
using Image Lab 5.0 software from Bio-Rad Laborato-
ries (RRID:SCR_014210) and a molecular weight marker 
(RPN800E; GE Healthcare, Chalfont St. Giles, Buck-
inghamshire, UK). Linear adjustments of contrast and 
brightness were applied to entire Western blot images. 
Nonlinear adjustments were not applied.
P‑gp transport activity and p‐gp‐mediated hAβ42 
transport
P-gp transport activity levels and P-gp-mediated Aβ 
transport were determined as previously described [9, 
28, 29]. To determine P-gp transport activity, freshly iso-
lated brain capillaries were incubated with 2 µM of the 
P-gp-specific substrate NBD-cyclosporin A (NBD-CSA) 
in DPBS for 1 hour. To assess P-gp-mediated hAβ42 
transport activity, brain capillaries were incubated with 5 
µM fluorescein-hAβ42 in DPBS for 1 hour. Images of 10 
capillaries per treatment group were captured by confo-
cal microscopy using the 488 nm line of an argon laser 
of a Leica TCS SP5 confocal microscope with a 63 × 1.2 
NA water immersion objective (Leica Instruments, Wet-
zlar, Germany). NBD-CSA fluorescence in the capil-
lary lumen was measured in each image using Image J 
v.1.48v (Wayne Rasband, NIH, USA; RRID:SCR_003070). 
Specific, luminal NBD-CSA or fluorescein-hAβ42 
fluorescence were measured as the difference between 
total luminal fluorescence and fluorescence in the pres-
ence of 5 µM PSC833, a P-gp-specific inhibitor [9, 28, 29].
Aβ immunostaining of brain capillaries
Freshly isolated brain capillaries were immunostained 
for hAβ40 and hAβ42 using a method described in previ-
ous studies [9]. Mouse brain capillaries were fixed with 
3% paraformaldehyde/0.25% glutaraldehyde for 30 min 
at room temperature and subsequently washed with 
PBS. Fixed capillaries were treated with 0.5% Triton 
X-100 for 30 min, washed with PBS and blocked with 1% 
BSA/DPBS for 60 min. Capillaries were incubated over-
night using a 1:250 dilution (4 µg/ml) of primary rabbit 
polyclonal antibody to human Aβ1-40 (hAβ40; ab12265, 
Abcam, Cambridge, MA, USA; RRID:AB_298985) or 
primary rabbit polyclonal antibody to human Aβ1-
42 (hAβ42; ab12267, Abcam, Cambridge, MA, USA; 
RRID:AB_298987). Capillaries were washed with 1% 
BSA/PBS for 60 min and incubated with secondary 
Alexa-Fluor 488-conjugated goat anti-rabbit IgG (1:1000, 
1 µg/ml; Invitrogen, Carlsbad, CA, USA; RRID:AB 
2,576,217) for 1  h at 37 °C. Nuclei were counterstained 
with 1 µg/ml DAPI (MilliporeSigma, Burlington, MA 
USA;RRID:SCR_014366). Immunofluorescence of hAβ40 
and hAβ42 was visualized by confocal microscopy (Leica 
TCS SP5 confocal microscope, 62 × 1.2 NA water objec-
tive, Leica Instruments, Weltzar, Germany). Brain capil-
lary plasma membrane immunofluorescence of hAβ40 
and hAβ42 was measured for each capillary with ImageJ 
software v1.48 as previously described [9, 23]. A 10 × 10 
grid was superimposed on each image and fluorescence 
measurements of capillary membranes were taken 
between intersecting grid lines. The fluorescence inten-
sity for each capillary was the mean of three measure-
ments per capillary.
hAβ40 and hAβ42 ELISA
Human Aβ40 and Aβ42 levels in plasma and brain sam-
ples were determined by ELISA following the manufac-
turer’s protocols (KHB3482 (sensitivity: < 6 pg/ml) and 
KHB3442 (sensitivity: < 10 pg/ml); Invitrogen, Cama-
rillo, CA, USA). Plasma samples were centrifuged at 
5000 g for 5 min at 4 °C, and then diluted with standard 
diluent buffer provided in the kit (hAβ40: 1:50 dilution; 
hAβ42: 1:4 dilution). Brain samples were homogenized 
in guanidine Tris-HCl buffer (5 M, pH 8) and diluted in 
DPBS containing 5% BSA and 0.03% Tween-20 (hAβ40: 
1:20 dilution; hAβ42: 1:5 dilution). Diluted samples were 
centrifuged at 16,000g for 20 min at 4 °C; the superna-
tant was analyzed by ELISA. Absorbance (450 nm) was 
measured using a Synergy™ H1 Hybrid Multi-Mode 
Reader (BioTek, Winooski, VT, USA). A standard curve 
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was plotted using Gen5™ software v2.07 to determine the 
concentration of hAβ40 and hAβ42 in plasma and brain 
samples; values obtained at 450 nm were corrected for 
background absorbance; four parameter logistic ELISA 
curve fitting was used.
Results
We previously reported that hAβ40 triggers degradation 
of P-gp at the blood-brain barrier [22, 23]. We found that 
hAβ40 activates the ubiquitin-proteasome system, which 
leads to internalization and proteasomal degradation of 
the transporter [22, 24]. Further, we showed that inhibi-
tion of intracellular trafficking with microtubule inhibi-
tors blocks proteasomal degradation of P-gp in isolated 
brain capillaries [22]. The present study extends these 
findings to an in vivo strategy designed to protect P-gp 
from degradation by blocking transporter internalization.
Effect of NCZ on P‑gp protein expression and transport 
activity
Microtubule inhibitors, such as nocodazole, have been 
shown to disrupt intracellular trafficking and internaliza-
tion of membrane proteins, such as P-gp [22, 30]. In the 
present study, we used transgenic hAPP mice (Tg2576 
model), one of the best characterized AD models that 
overexpresses human APP which leads to Aβ brain 
deposits [31]. At 8-weeks of age, hAPP mice have accu-
mulation of human Aβ in the brain and show reduced 
P-gp protein expression and transport activity at the 
blood-brain barrier [9, 23]. We dosed 8-week old hAPP 
mice (n = 15) with the microtubule inhibitor nocoda-
zole (NCZ; 5 mg/kg, i.p.) once every three days for two 
weeks (Table 1). A second group of hAPP mice received 
NCZ once every three days and on the two days between 
NCZ injections, this group of mice also received the P-gp 
inhibitor cyclosporin A (CSA; 25  mg/kg, p.o.; n = 15). 
Note that the group of NCZ-CSA-treated hAPP mice 
served as a control for P-gp transport activity to account 
for NCZ-treatment effects that depend on P-gp transport 
activity. Wild Type (WT; n = 10) mice and hAPP control 
mice (n = 15) received vehicle.
We found that after 14 days of treatment, P-gp pro-
tein expression levels in brain capillary membranes 
from NCZ-treated hAPP mice were comparable to those 
observed in WT mice (Fig.  1a). The same effect was 
observed in NCZ-CSA-treated mice. In contrast, vehi-
cle-treated hAPP mice showed significantly decreased 
P-gp protein expression levels. Western blots were 
quantified by optical density analysis and normalized to 
β-actin (Table 2). Optical density measurements of P-gp 
protein expression levels (n = 3, normalized to β-actin, 
SEM, p-value) are reported as percentage relative to 




Fig. 1  Effect of NCZ on P-gp protein expression and transport 
activity. a Western Blot for P-gp showing bands for brain capillary 
membranes isolated from vehicle-treated wild-type (WT), 
vehicle-treated hAPP mice, hAPP mice dosed with 5 mg/kg NCZ and 
hAPP mice dosed with a combination of NCZ and CSA (5/25 mg/kg). 
β-Actin was used as protein loading control; pooled tissue (WT: 10 
mice; hAPP: 15 mice; hAPP-NCZ: 15 mice, hAPP-NCZ/CSA: 15 mice). 
Data were normalized to β-Actin. b Representative confocal images 
showing accumulation of P-gp-specific substrate NBD-CSA in isolated 
brain capillaries from WT, hAPP, hAPP-NCZ and hAPP-NCZ/CSA mice 
after a 1 hour incubation (steady state; 2 µM NBD-CSA). c Data after 
digital image analysis using ImageJ. Specific NBD-CSA fluorescence 
is the difference between total luminal NBD-CSA fluorescence and 
NBD-CSA fluorescence in the presence of the P-gp-specific inhibitor 
PSC833 (5 µM). Statistics: Data per group are given as mean ± S.E.M. 
for 10 capillaries from one preparation [pooled tissue: WT (10 mice), 
hAPP (15 mice), hAPP-NCZ (15 mice), hAPP-NCZ/CSA (15 mice)]. 
Shown are arbitrary fluorescence units (scale 0–255). ***, significantly 
lower than control, p < 0.001
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Tukey’s HSD post hoc test); hAPP-NCZ: 102 ± 7% 
(Δ = 2%; p = 1.00; Tukey’s HSD post hoc test), and hAPP-
NCZ/CSA: 91 ± 6% (Δ=-9%; p = 0.83; Tukey’s HSD post 
hoc test).
We also determined P-gp transport activity levels by 
live-cell imaging of isolated brain capillaries according to 
a previously established protocol [9, 22, 25, 28]. Briefly, 
freshly isolated brain capillaries are transferred onto a 
glass cover slip and incubated for 1 hour with the fluo-
rescent P-gp substrate NBD-cyclosporin A (NBD-CSA, 
2 µM). Brain capillaries are then imaged using confocal 
microscopy and fluorescence of NBD-CSA accumulation 
in the capillary lumen is measured by quantitative image 
analysis using ImageJ. Changes in luminal NBD-CSA 
fluorescence compared to WT control indicate changes 
in P-gp transport activity. Thus, luminal NBD-CSA fluo-
rescence is an indirect measure of P-gp transport activ-
ity. Figure  1b shows representative confocal images of 
brain capillaries isolated from WT mice, hAPP mice, 
NCZ-treated hAPP mice, and hAPP mice treated with 
the combination of NCZ-CSA after a one-hour exposure 
to 2 µM NBD-CSA. Image analysis shows that specific 
luminal NBD-CSA fluorescence levels in the lumens of 
brain capillaries from hAPP mice were decreased by 76% 
(p < 0.0001; Tukey’s HSD post hoc test) compared to levels 
in capillaries from WT mice (Fig. 1c). Luminal NBD-CSA 
fluorescence levels in brain capillaries from NCZ-treated 
hAPP mice were increased by 26% relative to levels meas-
ured in capillaries from WT mice (p = 0.03; Tukey’s HSD 
post hoc test). Compared to WT mice, luminal NBD-
CSA fluorescence levels in brain capillaries from NCZ-
treated hAPP mice that received CSA were reduced by 
92%. This decrease in luminal NBC-CSA fluorescence is 
comparable to that found in vehicle-treated hAPP mice 
(p < 0.0001; Tukey’s HSD post hoc test). Thus, we found 
decreased luminal NBD-CSA fluorescence in brain cap-
illaries isolated from untreated hAPP mice and NCZ-
CSA-treated hAPP mice, whereas luminal NBD-CSA 
fluorescence levels in brain capillaries from NCZ-treated 
hAPP mice were similar to those observed in capillaries 
from WT mice. Note that we previously published a con-
trol experiment showing that nocodazole alone has no 
effect on P-gp protein expression and transport activity 
in isolated brain capillaries [22]. Thus, it is unlikely that 
the observed effects are due to nocodazole-mediated 
induction of P-gp protein expression.
In summary, the findings described in Fig. 1 show that 
treating hAPP mice with NCZ for two weeks restored 
P-gp protein expression and transport activity levels in 
brain capillaries. The data presented here together with 
our previously published work suggest that NCZ likely 
prevents P-gp internalization and degradation [22, 23].
Effect of NCZ on p‐gp‐mediated Aβ transport in hAPP mice
Next, we assessed P-gp-mediated transport of fluores-
cent labeled hAβ42 in isolated brain capillaries from 
mice in all four treatment groups. In these experiments, 
isolated brain capillaries were incubated to steady state 
with fluorescein-hAβ42 (FL-hAβ42; 5 µM) for 1 hour 
before we imaged the capillaries with a confocal micro-
scope. FL-hAβ42 fluorescence in capillary lumens was 
analyzed by quantitative image analysis [9, 22, 25, 28]. 
Figure  2a shows representative confocal images of iso-
lated brain capillaries incubated to steady state with 
5 µM FL-hAβ42. These images show reduced luminal 
FL-hAβ42 fluorescence in capillaries from vehicle-treated 
hAPP mice and in hAPP mice treated with NCZ-CSA 
compared to WT and NCZ-treated hAPP mice. Note 
that CSA is a competitive P-gp inhibitor, and therefore, 
P-gp-mediated FL-hAβ42 transport is reduced in isolated 
capillaries from hAPP mice that received the combina-
tion NCZ-CSA. Image analysis shows that in capillaries 
from hAPP mice, luminal FL-hAβ42 fluorescence was 
decreased by 68% (p = 0.0023; Tukey’s HSD post hoc test) 
compared to capillaries from WT mice (Fig. 2b). In brain 
capillaries from NCZ-CSA-treated hAPP mice, luminal 
FL-hAβ42 fluorescence is significantly decreased by 68% 
(p = 0.0007; Tukey’s HSD post hoc test) compared to that 
in capillaries from WT control mice. In contrast, luminal 
FL-hAβ42 fluorescence in capillaries from NCZ-treated 
hAPP mice was comparable to levels found in WT con-
trol mice (Δ = 27%; p = 0.27; Tukey’s HSD post hoc test).
Together, the data in Figs.  1 and 2 suggest that treat-
ment of hAPP mice with NCZ protects P-gp protein 
expression and transport activity at the blood-brain 
barrier.
Effect of NCZ treatment on ALT levels
During the two-week treatment with NCZ, animals 
were continuously monitored by daily health checks, 
and we observed no NCZ-induced visible adverse 
effects. We also determined alanine-aminotransferase 
(ALT) activity levels in liver tissue samples from 
treated and untreated animals after the 2-week dos-
ing period to determine potential NCZ-induced liver 
Table 2  Western blot analysis of P-gp protein expression levels 
in brain capillaries isolated from WT and hAPP mice (Fig. 1a)
Data were obtained from optical density measurements and were normalized to 
β-actin levels; values are given as %control ± SEM (n = 3)
*Indicates statistical significance determined at the 0.05 level for each endpoint 
compared to control using Dunnett’s many-to-one t-test
Protein Wild Type hAPP hAPP-NCZ hAPP-NCZ/CSA
 P-gp 100 ± 13 51 ± 3* 102 ± 7 91 ± 6
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toxicity. Increased ALT activity levels can be an indica-
tor of liver damage and toxicity and are generally used 
in the clinic to monitor overall health, in particular 
to detect drug-induced liver toxicity [32]. ALT activ-
ity levels from all treatment groups ranged between 
2,599 and 2,881 mU/ml; there was no significant dif-
ference between any of the groups  (F3,51=1.1, p = 0.36; 
ANOVA; Fig. 3).
These data show that the 2-week NCZ treatment 
did not affect ALT activity, which suggests that NCZ 
did not induce liver damage in the animals during the 
treatment phase. More studies are necessary to fully 
evaluate the safety of NCZ, especially with regard to a 
long-term treatment regimen.
Effect of NCZ treatment on Aβ levels in hAPP mice
Next we evaluated the effect of NCZ treatment on hAβ40 
and hAβ42 levels in plasma, brain capillary membranes, 
and brain tissue.
We used ELISA to determine plasma hAβ40 and hAβ42 
protein levels (Fig. 4a, b). hAβ40 levels were in the range 
3,656–3,797 pg/ml with no significant difference between 
groups  (F2,42, p = 0.98; ANOVA). For hAβ42, we found 
levels ranging from 200 to 244 pg/ml, also with no sig-
nificant difference between groups  (F2,42=0.13, p = 0.88; 
ANOVA). This finding is consistent with rapid Aβ clear-
ance from blood by the liver and the kidney [33]. Note 
that samples from WT mice were not included in the 
analysis since WT mice do not express human Aβ.
One characteristic of AD is accumulation of Aβ in 
blood vessel walls [27, 34]. We therefore determined cap-
illary-associated hAβ levels with immunohistochemistry. 
Freshly isolated brain capillaries were immunostained for 
hAβ40 and hAβ42, imaged with a confocal microscope, 
followed by image analysis of capillary membranes. Brain 
capillaries isolated from treated and untreated hAPP 
mice stained positive for both hAβ40 and hAβ42 (Fig. 5a, 
b). Image analysis revealed that NCZ-treatment lowered 
capillary-associated hAβ40 by 37% (p = 0.0004; Tukey’s 
HSD post hoc test) compared to capillaries from vehicle-
treated hAPP mice. For hAβ42, no difference was found 
between treatment groups (p = 0.91; Tukey’s HSD post 
hoc test).
Finally, we analyzed hAβ40 and hAβ42 brain levels by 
Western blotting and ELISA. Western blotting showed 
reduced hAβ40 and hAβ42 protein levels in brain tissue 
a
b
Fig. 2  Effect of NCZ on P-gp-Mediated hAβ42 transport. a 
Representative confocal images of isolated brain capillaries showing 
accumulation of fluorescein-hAβ42 in capillary lumens after a 1 hour 
incubation (steady state; 5 µM fluorescein-hAβ42). b Data after digital 
image analysis using ImageJ. Specific fluorescein-hAβ42 fluorescence 
is the difference between total luminal fluorescein-hAβ42 
fluorescence and fluorescein-hAβ42 fluorescence in the presence of 
the P-gp-specific inhibitor PSC833 (5 µM). Statistics: Data per group 
are given as mean ± S.E.M. for 10 capillaries from one preparation 
(pooled tissue: WT (10 mice), hAPP (15 mice), hAPP-NCZ (15 mice), 
hAPP-NCZ/CSA (15 mice)). Shown are arbitrary fluorescence units 
(scale 0–255). ***, significantly lower than control, p < 0.001
Fig. 3  NCZ shows no effect on ALT activity levels. ALT activity levels 
(mU/ml) in liver samples from WT, hAPP, hAPP-NCZ and hAPP-NCZ/
CSA mice. Data are given for each animal: WT (n = 10), hAPP (n = 15), 
hAPP-NCZ (n = 15), hAPP-NCZ/CSA (n = 15). Statistics: ANOVA; Data 
between groups are not significantly different
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samples from NCZ-treated hAPP mice compared to 
untreated hAPP mice (Fig.  6a). In contrast, hAβ pro-
tein levels in brain tissue from NCZ-treated mice that 
also received CSA to control for P-gp transport activ-
ity appeared similar to those detected in brain tissue 
from vehicle-treated hAPP mice. Using ELISA, we 
found that in NCZ-treated hAPP mice hAβ40 brain lev-
els were reduced by 48% (p < 0.0001; Tukey’s HSD post 
hoc test) and hAβ42 brain levels were reduced by 30% 
(p = 0.0008; Tukey’s HSD post hoc test) compared to 
vehicle-treated hAPP mice (Fig. 6b, c).
In summary, our data presented here together with 
our previously publish work support our proposed 
mechanism that blocking P-gp internalization with 
NCZ protects P-gp from proteasomal degradation, 
which helps reduce Aβ brain load in hAPP mice (Fig. 7).
Discussion
We previously showed that hAβ40 triggers (1) ubiquitina-
tion, (2) internalization, and (3) proteasomal degradation 
of blood-brain barrier P-gp, which results in decreased 
P-gp protein expression and transport function [22, 24]. 
We further demonstrated that preventing P-gp ubiqui-
tination preserves P-gp protein expression and trans-
port activity at the blood-brain barrier, which resulted 
in lower Aβ brain levels in vivo [23]. Our present study 
builds on this existing work and extends these findings by 
targeting Aβ-driven P-gp internalization in vivo.
For the present study, we treated hAPP mice with the 
microtubule inhibitor, nocodazole (NCZ), and evaluated 
the effects of NCZ on P-gp protein expression and trans-
port activity and hAβ burden. We found that isolated 
brain capillaries from hAPP mice treated with NCZ had 
P-gp expression and transport activity levels compara-
ble to those from WT control mice (Figs.  1 and 2). No 
adverse effects were noticed during nocodazole treat-
ment, accordingly, ALT activity levels in liver samples 
were similar across all groups. The absence of adverse 
effects is likely due to the relatively short treatment phase 
of 2 weeks. (Fig. 3). No difference in hAβ40 and hAβ42 
levels was detected in plasma samples from treated and 
un-treated hAPP mice (Fig. 4). We found that NCZ treat-
ment decreased membrane-associated hAβ40 levels in 
hAPP mice (Fig. 5) and show that hAβ40 and hAβ42 lev-
els were significantly lower in brain samples from NCZ-
treated hAPP mice compared to those in untreated hAPP 
mice and hAPP-NCZ/CSA control mice (Fig.  6). Based 
on these data we conclude that NCZ treatment protects 
P-gp protein expression and transport activity levels at 
the blood-brain barrier and results in reduced Aβ levels 
(Fig. 7). This effect is likely due to the inhibition of P-gp 
internalization and degradation by NCZ. In the follow-
ing sections we discuss our findings in the context of the 
existing literature.
One mechanism that accounts for changes in P-gp-
mediated transport is trafficking between vesicular 
compartments and the plasma membrane. Arias and col-
leagues were the first to report membrane trafficking of 
several ABC transporters, including P-gp, bile salt export 
pump (BSEP), and Mrp2 at the bile canalicular membrane 
of hepatocytes [35, 36]. These authors showed cycling of 
P-gp between intracellular pools and the plasma mem-
brane by demonstrating insertion of P-gp into the cana-
licular membrane in response to cyclic AMP (cAMP) and 
taurocholate. This effect was independent from protein 
biosynthesis. In addition, the microtubule disruptor, col-
chicine, and the PI3 kinase inhibitor, wortmannin, inhib-
ited membrane insertion of P-gp. On the other hand, it 
was also demonstrated that cholestasis caused retrieval 
of P-gp from the canalicular membrane into intracellular 
a
b
Fig. 4  NCZ treatment has no effect on hAβ40 and hAβ42 plasma 
levels in hAPP mice. a hAβ40 levels (pg/ml) and b hAβ42 levels (pg/
ml) in plasma samples from WT, hAPP, hAPP-NCZ and hAPP-NCZ/
CSA mice. Data are given for each animal: WT (n = 10), hAPP (n = 15), 
hAPP-NCZ (n = 15), hAPP-NCZ/CSA (n = 15). Statistics: ANOVA; Data 
between groups are not significantly different
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vesicles [35, 37, 38]. Sai et al. visualized P-gp trafficking 
between the pericanalicular region and the bile cana-
licular membrane in a hepatic cell line expressing GFP-
tagged P-gp [36]. These researchers also demonstrated an 
involvement of microtubules in P-gp membrane traffick-
ing. Their results show that in hepatocytes, vesicular traf-
ficking of P-gp depends on microtubules and modulates 
transport activity at the canalicular membrane. Recent 
studies indicate that P-gp trafficking is also an impor-
tant mechanism to regulate P-gp transport activity at the 
blood-brain barrier. Hawkins and colleagues found that 
the vascular endothelial growth factor (VEGF) triggers 
removal of P-gp from the luminal membrane resulting in 
decreased P-gp transport activity in brain capillaries [39]. 
This study provided first evidence that loss of P-gp trans-
port activity can be due to P-gp internalization shift-
ing the transporter into an intracellular compartment 
where it no longer functions as an efflux transporter. 
The effect of VEGF was blocked by nocodazole, whereas 
proteasome inhibition had no effect. In a series of elegant 
studies, McCaffrey, Tome and colleagues discovered 
that peripheral inflammatory pain leads to caveolin-
1-mediated trafficking of P-gp at the blood-brain barrier 
[40–42]. Caveolin-1 is a scaffolding protein that has been 
shown to interact with P-gp [43]. In the case of periph-
eral pain, P-gp levels increased at the luminal membrane 
of the brain capillary endothelium. In an in vitro study, 
Noack et al. found that drugs such as mitomycin C trig-
ger P-gp trafficking in the hCMEC/D3 cell line [44]. 
Redistribution of P-gp from intracellular pools to the 
cell membrane occurred within 2 hours of incubation 
with mitomycin C. Little is known about signaling steps 
through which P-gp internalization and/or trafficking of 
the transporter to the membrane occurs at the blood-
brain barrier. Work in liver and cancer cells showed that 
Src kinase interacts with P-gp and that this interaction is 
likely responsible for P-gp membrane localization [45]. 
Several studies found that Pim-1 kinase phosphorylates 
a b
c d
Fig. 5  NCZ lowers Aβ levels in brain capillaries. Representative confocal images of isolated brain capillaries immunostained for a hAβ40 and b 
hAβ42. Data after digital image analysis of membrane-associated c hAβ40- and (D) hAβ42-immunofluorescence using ImageJ. Statistics: Data per 
group are given as mean ± S.E.M. for 10 capillaries from one preparation [pooled tissue: WT (n = 10), hAPP (n = 15), hAPP-NCZ (n = 15), hAPP-NCZ/
CSA (n = 15)]. Shown are arbitrary fluorescence units (scale 0–255). For hAβ40 p < 0.001; ***, significantly lower than control. For hAβ42, data 
between groups are not significantly different
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P-gp, which seems to be necessary for plasma membrane 
localization of the transporter [46–49]. However, the 
role Pim-1 plays in P-gp internalization and trafficking 
still needs to be determined in more detail. We recently 
observed that nanomolar concentrations of hAβ40 trig-
ger P-gp degradation through the ubiquitin-proteasome 
system [22, 24]. Inhibiting protein ubiquitination, pro-
tein trafficking, and the proteasome prevented hAβ40-
mediated decrease of P-gp protein expression and 
transport activity. In a subsequent study we showed 
that inhibiting the ubiquitin-activating enzyme E1 with 
PYR41 prevented P-gp ubiquitination in vivo prevented 
P-gp degradation and lowered Aβ brain levels [23]. The 
present study expands this work by treating hAPP mice 
with the microtubule inhibitor nocodazole in  vivo and 
demonstrates that P-gp expression and activity can be 
protected with NCZ. In both studies, we used prefron-
tal cortex for Aβ quantification since this brain region is 
highly affected in AD and shows early signs of Aβ deposi-
tion, while the remaining part of the cerebral cortex was 
used to isolate brain capillaries. Comparing the data from 
our previous study with PYR41 and the data from the 
a
b c
Fig. 6  NCZ lowers Aβ brain levels. a Western Blot showing hAβ40 and hAβ42 protein expression levels in brain tissue samples from vehicle-treated 
WT, vehicle-treated hAPP mice, hAPP mice dosed with 5 mg/kg NCZ and hAPP mice dosed with a combination of NCZ and CSA (5/25 mg/kg). 
β-Actin was used as protein loading control. b hAβ40 and c hAβ42 levels (pg/ml) in brain tissue samples from hAPP, hAPP-NCZ and hAPP-NCZ/CSA 
mice determined by ELISA. Statistics: ***, significantly lower than control, p < 0.001; **, significantly lower than control, p < 0.01
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present study with nocodazole, we found no difference 
between the effects of PYR41 and nocodazole on protect-
ing P-gp from degradation and decreasing Aβ brain levels 
(Aβ40: NCZ 48% vs. PYR41 53% and Aβ42: NCZ 30% vs. 
PYR41 33%).
Drug combinations are often applied to treat complex 
diseases and synergistic effects among different drugs 
hold the promise to achieve larger effects with lower 
doses and reduced side effect profiles [50]. Drugs acting 
on the same signaling pathway by targeting different sign-
aling molecules are more likely to produce synergistic 
effects. Thus, based on our proposed signaling pathway 
(Fig.  7), inhibiting both ubiquitination and internaliza-
tion at the same time has the potential for synergistic 
effects on preserving P-gp and lowering Aβ brain levels. 
Clearly, future studies are needed to demonstrate such 
potentially synergistic effects.
Conclusions
Based on our previously published work and the data 
presented here, we conclude that inhibiting P-gp inter-
nalization with a microtubule inhibitor could be used to 
protect P-gp from degradation which could help lower 
Aβ brain levels in AD [22, 23]. Therefore, modulating 
P-gp trafficking could be a potential new therapeutic 
target to help protect P-gp at the blood-brain barrier in 
AD. Currently, microtubule inhibitors are approved for 
solid and hematologic cancers and include agents such as 
taxanes, vinca alkaloids, and epothilones. Several drugs 
including vincristine and colcemid are similar to nocoda-
zole in that they interfere with microtubule polymeriza-
tion [51]. Thus, there is the possibility of therapeutically 
targeting P-gp trafficking in AD. However, neuronal 
activity depends to a large extent on vesicular trafficking, 
and thus, a microtubule inhibitor would be needed that is 
suitable and safe for the use in CNS disorders including 
AD. Clearly, more work is needed to evaluate the poten-
tial therapeutic benefit of blocking P-gp internalization in 
AD.
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